Stock listing
Cboe Canada:QPT Quest PharmaTech Inc. Stock
Canadian listing (Cboe Canada) of Quest PharmaTech Inc. · home listing TSXV:QPT
Follow Quest PharmaTech Inc. into a list and get an email when it puts out news.
Home listing price · TSXV:QPT
$0.02 CAD 0.00 (0.0%)
Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TSXV:QPT
- Day range
- $0.02 – $0.02 CADNov 19, 2026
- Market cap
- $3.38M CADAt the close on Nov 19, 2026 · price × 169.1M shares outstanding
- 52-week range
- $0.02 – $0.05 CADLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $170 CADMedian day 0 shares · 50 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSXV:QPT · Home | $0.02 CAD | 0.00 (0.0%) | — | $0.02 | $0.02 | $0.02 | $0.02 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TSXV:QPT · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 1,250 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 67,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 90,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 9,100 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | -0.01 | -33.3% | $0.02 | $0.02 | $0.02 | 8,100 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 5,600 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | +0.01 | +50.0% | $0.03 | $0.03 | $0.03 | 25,500 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 2,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 120,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 1,500 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | -0.01 | -33.3% | $0.02 | $0.02 | $0.02 | 4,000 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 16,000 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 0 | |
| $0.03 | +0.01 | +50.0% | $0.03 | $0.03 | $0.03 | 105,200 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 10,000 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 0 | |
| $0.02 | 0.00 | 0.0% | $0.02 | $0.02 | $0.02 | 10,000 |
- Ticker
- Cboe Canada:QPT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Cboe Canada
- Currency
- CAD
What changed lately
Latest news release · Sep 25, 2026
Quest PharmaTech Announces Change of Chief Executive Officer
Latest news
Quest PharmaTech Announces Change of Chief Executive Officer
Sep 25, 2026
Closed $0.03 (0.0%) on Sep 28, 2026
Quest PharmaTech Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 142 in all · newest Sep 25, 2026 · oldest 2005
- Decks
- 1 deck · latest January 2016
Where Quest PharmaTech Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSXV:QPT · Home listing | TSXV | Canada | CAD |
| OTC:QPTFF | OTC | United States | USD |
| Cboe Canada:QPT · This page | Cboe Canada | Canada | CAD |
Valuation
Price/book 0.1× against a median of 0.3×: 2nd lowest of 9 Biotechnology companies shown. Statements: Year to Jan 31, 2026 · balance Jul 31, 2026 · price Nov 19, 2026
- Enterprise value
- $3.30M CAD
- P/E
- 0.7×
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P/TSX Composite
- 1.90
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| PharmaCyte Biotech, Inc. · NASDAQ:PMCB | US$2.25M | −US$15.59M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.97 |
| Median of the others | US$2.39M | −US$907,868 | 14.7× | 0.3× | −301.9% | 0.0× | 1.19 |
Team and board
Officers
| Officer | Role |
|---|---|
| Madi Madiyalakan | Chief Executive Officer, Director |
| Pierre Vermette | Chief Financial Officer |
| J. Mark Lievonen | Director, Chairman of the Board |
Board
| Director | Role |
|---|---|
| Bradley J. Glass | Director |
| Jeffrey Shon | Director |
| Madi Madiyalakan | Chief Executive Officer, Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Jun 29, 2023 · After close | 0.0% |
| Q2 2023 | Sep 26, 2022 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AmrutBio — Investor Presentation (January 2016) | Investor deck | 22 slides | January 2016 |
Financials
Annual, in CAD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38.9K | 2.57K |
| Cost of revenue | 17.7K | 1.19K | ||||||||
| Gross profit | 21.1K | 1.38K | ||||||||
| Research and development | 242.3K | 329.2K | 542.9K | 336.2K | 170.2K | 212.5K | 11.3M | 6.27M | 5.51M | 2.10M |
| Selling, general and administrative | 468.9K | 488.1K | 773.0K | 498.0K | 620.3K | 857.8K | 2.37M | 2.78M | 2.31M | 2.22M |
| Operating income | -711.3K | -817.3K | -1.32M | -834.2K | -790.6K | -1.07M | -13.6M | -9.04M | -7.79M | -4.32M |
| Depreciation and amortization | 0 | 2.97K | 13.5K | 38.6K | 39.3K | 42.8K | 7.51K | 12.0K | 14.9K | |
| EBITDA | -817.3K | -1.31M | -820.7K | -752.0K | -1.03M | -13.6M | -9.03M | -7.78M | -4.30M | |
| Interest expense | 20.3K | 22.6K | 20.7K | 21.0K | 13.1K | 7.77K | 13.7K | 4.42K | 0 | 0 |
| Income before tax | 5.00M | -1.80M | -3.02M | -7.33M | -85.0M | 190.1M | -13.3M | -8.64M | -9.11M | -4.42M |
| Income tax | 0 | 0 | ||||||||
| Net income | 5.00M | -1.80M | -3.02M | -7.33M | -85.0M | 190.1M | -6.18M | -4.39M | -5.09M | -4.13M |
| Earnings per share, basic | 0.03 | -0.01 | -0.02 | -0.04 | -0.51 | 1.13 | -0.04 | -0.03 | -0.03 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 14.4K | 205.1K | 717.0K | 374.7K | 264.3K | 199.1K | 2.15M | 347.3K | 416.4K | 1.22M |
| Short-term investments | 0 | 300.0K | 3.11M | 10.9M | 8.27M | |||||
| Receivables | 221.3K | 320 | 32.7K | 10.9K | 14.3K | 23.0K | 18.5K | |||
| Inventory | 0 | 364 | 90.1K | |||||||
| Current assets | 32.9K | 225.3K | 835.5K | 621.5K | 288.1K | 281.4K | 2.89M | 4.30M | 12.4M | 10.2M |
| Property, plant and equipment | 2.97K | 16.5K | 55.0K | 99.2K | 19.7K | 25.5K | 26.8K | |||
| Total assets | 27.8M | 22.6M | 24.5M | 84.4M | 91.0M | 175.6M | 4.45M | 5.81M | 12.8M | 11.4M |
| Accounts payable | 106.4K | 108.6K | 85.1K | 5.86M | 506.7K | 930.2K | 733.5K | |||
| Current liabilities | 1.33M | 1.17M | 1.32M | 1.11M | 622.6K | 375.4K | 20.9M | 10.1M | 9.95M | 733.5K |
| Total liabilities | 1.33M | 1.17M | 1.32M | 1.11M | 622.6K | 389.4K | 20.9M | 10.1M | 9.95M | 733.5K |
| Shareholders' equity | 26.4M | 21.4M | 23.2M | 83.3M | 90.4M | 175.2M | -15.3M | -10.3M | -7.38M | 11.0M |
| Shares outstanding | 169.1M | 169.1M | 169.1M | 169.1M | 168.2M | 168.2M | 167.7M | 167.4M | 167.1M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -190.7K | -511.9K | -342.4K | -554.7K | -170.8K | -2.52M | -6.38M | -6.91M | -7.33M | -4.61M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | -38.0K | -35.9K | -1.63K | -8.72K | -8.94K |
| Free cash flow | -190.7K | -511.9K | -342.4K | -554.7K | -170.8K | -2.55M | -6.38M | -6.91M | -7.33M | -4.62M |
| Cash from investing | -14.0K | -14.0K | 262.0K | 2.78M | 8.26M | -2.98M | -24.8K | |||
| Cash from financing | 0 | 684.7K | 679.0K | 250.0K | 299.0K | 5.40M | -1.42M | 9.46M | 5.11M | |
| Share buybacks | 9.30M | 9.30M | ||||||||
| Change in cash | -190.7K | -511.9K | 342.3K | 110.3K | 65.2K | -1.95M | 1.81M | -69.1K | -805.5K | 433.3K |
Cap table
Built by 6ix from Quest PharmaTech Inc.’s releases
- Common shares
- 169,129,247
- Fully diluted
- 169,129,247
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 169,129,247 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 169,129,247 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bradley J. Glass | Director · Since at least Aug 27, 2025 |
| Jeffrey Shon | Director · Since at least Sep 25, 2026 |
| J. Mark Lievonen | Director, Chairman of the Board · Since at least Sep 25, 2026 |
| Madi R. Madiyalakan | Chief Executive Officer, Director · Since at least Sep 25, 2026 |
| Pierre Vermette | Chief Financial Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Quest PharmaTech Inc.